Search research articles
Contact Us
Filters
Showing results (251-260 of 256) with videos related to
Page
of 26
Sort By:
You have reached the last page of results.
This site can display upto 256 results.
Hepatology International
|
July 24, 2015
The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial
Jung Hyun Kwon, Si Hyun Bae, Youn Jae Lee, et al.
Pharmacogenetics and Genomics
|
August 8, 2013
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention
Mahn-Won Park, Sung Ho Her, Ho-Sook Kim, et al.
Thrombosis and Haemostasis
|
December 22, 2011
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy
Benjamin D Horne, Petra A Lenzini, Mia Wadelius, et al.
American Heart Journal
|
April 15, 2018
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)
Thomas O Bergmeijer, Jean-Luc Reny, Ruth E Pakyz, et al.
Clinical Pharmacology and Therapeutics
|
May 31, 2020
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium
Shefali Setia Verma, Thomas O Bergmeijer, Li Gong, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
September 11, 2019
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients
Joshua P Lewis, Joshua D Backman, Jean-Luc Reny, et al.
Page
of 26
Search research articles
Search
Showing results (251-260 of 256) with videos related to
Sort By:
Page
of 26
You have reached the last page of results.
This site can display upto 256 results.
Hepatology International
|
July 24, 2015
The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial
Jung Hyun Kwon, Si Hyun Bae, Youn Jae Lee, et al.
Pharmacogenetics and Genomics
|
August 8, 2013
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention
Mahn-Won Park, Sung Ho Her, Ho-Sook Kim, et al.
Thrombosis and Haemostasis
|
December 22, 2011
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy
Benjamin D Horne, Petra A Lenzini, Mia Wadelius, et al.
American Heart Journal
|
April 15, 2018
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)
Thomas O Bergmeijer, Jean-Luc Reny, Ruth E Pakyz, et al.
Clinical Pharmacology and Therapeutics
|
May 31, 2020
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium
Shefali Setia Verma, Thomas O Bergmeijer, Li Gong, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
September 11, 2019
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients
Joshua P Lewis, Joshua D Backman, Jean-Luc Reny, et al.
Page
of 26